Centrus Energy Zen Horizon Framework Deep-Dive Research

Hunting ten-year five-baggers among great growth stocks — pressing the upside question: "Can it get much bigger?"

• QHow high is its market ceiling? Is it expanding an existing pie, or creating an entirely new market?5/10

  A

  The ceiling is real, but it needs to be split into two parts: Centrus is mainly taking share in an existing pie that already exists and is being redistributed because of “de-Russification” (commercial LEU/SWU enrichment), while also betting on a new market that has not yet formed (HALEU for advanced reactors). The latter has more upside in imagination, but it barely exists today, and the likely landing point is skewed toward the 2030s.

  Start with the “expanding the existing pie” part: high certainty, limited ceiling. The 94 operating U.S. reactors need about 15 million SWU of enrichment each year, while domestic operating capacity is only about 4.9 million SWU (URENCO USA alone), so a structural gap clearly exists. Add the Russian uranium import ban, which fully prohibits imports starting 2028-01-01, and the fact that Russia previously supplied nearly 1/4 of U.S. enrichment needs, and a meaningful substitution opportunity opens up. But this is a mature market with slow total-volume growth and share redistribution among suppliers. It is not demand appearing out of thin air. How much Centrus can capture depends on how large its commercial capacity, not online until 2029, can scale. Meanwhile, DOE is also supporting Orano (a Tennessee $5B, 7.4M SWU/year new plant) and URENCO expansion, so while the pie grows, there will also be more people cutting it.

  Now look at the “creating a new market” part: HALEU is the real blue-sky element in the Centrus story. DOE estimates U.S. HALEU annual demand will reach about 50 metric tons/year by 2035. Current commercial supply outside Russia is almost zero, and Centrus is the only domestic HALEU producer that is operating and licensed by the NRC. This really is an early-mover position in an entirely new market. Practically speaking, however, the market’s size today is roughly zero. Centrus’s current HALEU output is only about 900 kg/year at demonstration scale, 100% sold to DOE, with no commercial customers. Its realization depends heavily on SMR projects from TerraPower, X-energy, Oklo, and others, and those projects are repeatedly delayed. TerraPower has already pushed Natrium startup from 2028 to 2030/2031.

  Conclusion: Centrus has one foot in “taking a slice of an existing pie under restructuring” (near-term, rigid demand, measurable ceiling), and the other foot in “getting first-mover position in a market that has not yet been born” (long-dated, option-like, with large imagined upside but late realization). What truly determines its ten-year ceiling is whether the latter can move from policy incubation to commercial volume. Paying for that ceiling today, however, is almost entirely paying option premium, not paying for already-realized market share.

  Jun 10, 2026
• QCan its revenue at least double over the next five years? Will growth be driven mainly by volume, price, or new businesses?4/10

  A

  Conclusion: A revenue doubling within five years is possible, but uncertain, and the timing most likely gets pushed to the very end of the window. In theory, the drivers touch volume, price, and new business, but the last three years of actual results point the other way: revenue has been basically flat, and the real volume engine does not come online until 2029.

  Start with the base and trend. Do not be fooled by the “growth stock” label. Centrus reported FY2025 total revenue of $448.7M, versus $320M in FY2023 and $442M in FY2024. Over the last three years it has almost gone sideways: FY2024’s +38% was driven by one-off high uranium sales and a doubling in Technical Solutions, while FY2025 uranium revenue plunged and SWU volume merely held total revenue roughly flat. The company’s own 2026 full-year guidance is only $450–500M, implying about +6% year over year at the midpoint. In other words, extrapolating from today’s actual results, a five-year doubling requires about 15% annualized growth, clearly above the company’s current growth path.

  Now break down the three drivers and test how reliable they are:

  • Price (SWU price): This is Centrus’s core beta. Spot SWU prices have risen from about $56 three years ago to about $188/SWU in 2025 (up about 3.4 times), but its current LEU supply is mainly delivered through long-term contracts (Russian TENEX to 2028, French Orano to 2030). High spot prices cannot immediately or fully flow through to the income statement, and spot prices are already at multi-year highs, leaving less marginal room for another sharp rise than in the past. Price can help, but it cannot support a doubling by itself.
  • Volume (self-produced SWU ramp): This is the real swing factor for a doubling, but there is a timing mismatch. Centrus’s current commercial enrichment capacity is effectively zero. The commercial-scale HALEU/LEU capacity target at Piketon is only around 2029. That means the first three to four years of the five-year window still rely on a purchase-and-resale trading model that is hard to scale materially; volume growth is concentrated in years 4–5 and depends on engineering arriving on time, without cost overruns, and with a smooth ramp.
  • New business (HALEU commercial orders + DOE funding): If the $900M DOE task order is finalized, it would significantly thicken Technical Solutions (the segment was already +47% in Q1'26), making it the most realistic medium-term incremental driver. But the order is still subject to negotiation, and HALEU still has zero commercial customers.

  Practical judgment: A doubling is not the base case. It is a moderately optimistic case that requires three things to happen at once: 2029 commercial capacity starts on schedule, SWU prices remain high, and DOE orders land. If any link is discounted, especially SMR delays that hurt capacity utilization, five-year revenue is more likely to stop in the $600–800M range rather than exceed $900M. This is also the financial reason the report rates it “Watch” rather than “Buy”: the growth story is long-dated, while near-term financials are still flat.

  Jun 10, 2026
• QAfter five years, what will take over as the next growth engine? Does this “second curve” exist today?4/10

  A

  Conclusion: Centrus’s “second curve” is HALEU commercialization. It does exist today, but it is still in an embryonic stage of policy incubation and zero commercial customers. Whether it can take over depends on whether the downstream advanced-reactor market is born on schedule. This differs from the usual “core cash cow + incubated new business” second curve at mature companies: Centrus’s near-term core business (LEU trading/enrichment) itself is just about to move from purchase-and-resale to self-production, so the commercialization of the second curve (HALEU) and the first curve are almost tied to the same 2029 timing point.

  Look at the quality of this second curve:

  It exists and has real first-mover status. Centrus is currently the only domestic HALEU producer that is operating and licensed by the NRC, and it completed the first delivery of >20kg HALEU in 2023-11. That was the first enriched uranium produced in 70 years by a facility using “American ownership + American technology.” The downstream demand picture is also being built: DOE estimates HALEU annual demand will reach about 50 metric tons/year by 2035, and AI giants have placed bets on advanced reactors (Amazon–X-energy, Google–Kairos). The direction of this curve is right.

  But its “commercial” scale today is roughly zero, and it is highly dependent on external events. Current HALEU output is about 900 kg/year, 100% sold to DOE, with no commercial customer. Commercial-scale capacity is only expected around 2029. More importantly, HALEU’s demand side (SMR projects) is being systematically delayed: TerraPower has pushed Natrium startup to 2030/2031 because of HALEU shortages, and schedule slippage is normal for first-of-a-kind reactor projects (NuScale’s flagship UAMPS project was outright canceled in 2023). The handoff point for the second curve is tied to a downstream clock Centrus does not control.

  There are also two possible “third curve” shoots, but they are even earlier: ① national-security “single-source” enrichment (DOE/NNSA defense demand for unobligated uranium material, where Centrus has a real exclusive position); ② value-added services such as the HALEU deconversion joint venture being discussed with Oklo. These directions are real, but they remain at the intent/negotiation stage and do not yet qualify as “engines.”

  Practical judgment: The second curve (HALEU commercialization) exists and has unique positioning. This is the fundamental reason Centrus deserves to be “Watched.” But today it is an engine that has ignited but is not yet connected to the grid: the fuel (DOE funding), the grid-connection timing (2029 capacity), and the power users (SMR customers) are all still on the way. Whether it can truly take over is essentially a bet on whether the new advanced-reactor industry can commercialize on schedule in the 2030s, not a bet on Centrus’s own execution alone. That is the biggest uncertainty in its growth narrative.

  Jun 10, 2026
• QWhat is its core competitive advantage? Will this moat widen or narrow over the next three to five years?5/10

  A

  Conclusion: Centrus’s moat is “narrow but real.” It rests on policy positioning and technology source, not scale or cost. Over the next three to five years, in the narrow band of “national security/HALEU first mover,” it will become deeper as capacity comes online, but across the broader band of “commercial enrichment uniqueness,” it will become narrower because DOE is actively cultivating competitors. In one sentence: depth increases, exclusivity declines.

  First pin down the moats that do exist (these are real):

  • “Only U.S.-owned + only U.S.-technology” enrichment capability: the AC100M centrifuge is 100% U.S.-developed, manufactured at its own Oak Ridge facility, and protected by ITAR export controls. It is the first facility of this kind to enter production since 1954 (Centrus: American Centrifuge).
  • Currently the only operating and NRC-licensed HALEU producer: it covers the 19.75% enrichment level needed for advanced reactors, while commercial HALEU supply globally is almost nonexistent outside Russia’s TENEX.
  • National-security “single-source” position: NNSA intends to procure certain enrichment activities from Centrus on a single-source basis because foreign-owned technologies (URENCO/Orano) are bound by “peaceful use” obligations and cannot be used for unobligated uranium material for defense purposes. This is its hardest exclusive position, and it should strengthen as capacity comes online.
  • Industry-level entry barriers: building a new enrichment plant requires about $5 billion in capex, NRC licensing takes years, technology is constrained by nuclear nonproliferation controls, and there are only a handful of commercial enrichers globally.

  Now mark the counterexamples that will make the moat “narrower” (these are often hidden by the narrative):

  • It is not “the only operating enrichment plant.” The only commercial-scale operating enrichment plant in the United States today is URENCO USA (Eunice, New Mexico, about 4.9 million SWU/year), which is foreign-owned and uses European technology. Centrus’s current commercial enrichment capacity is effectively zero, and commercial LEU capacity will only come online around 2029.
  • The “only” premium is being diluted by DOE itself. In the same 2026-01 round, DOE awarded the same $900M to Orano (LEU) and General Matter (HALEU). Orano plans a Tennessee $5B/7.4M SWU plant, and URENCO will also expand capacity by about 50%. This is a “multi-supplier” national strategy, not an exclusive handoff to Centrus. The next three to five years, when peer capacity comes online in concentration, are exactly the window in which moat exclusivity narrows.
  • A backlash risk runs underneath: its current largest SWU supplier is the sanctioned Russian TENEX (contract through 2028). The Russian ban creates demand upside while threatening to cut off the input it relies on for resale. The other side of this “moat” is “dependence on the banned counterparty,” which is itself a fragility.

  Practical judgment: The moat direction is “deeper ↑, narrower ↓.” As Piketon capacity comes online in 2029 and national-security single-source orders materialize, Centrus’s moat in the narrow band of “defense unobligated uranium material + domestic HALEU first mover” should deepen and its bargaining power should improve. But the sexiest narrative, “the only/monopoly U.S. enricher,” will be disproved and narrowed by DOE’s multi-supplier policy and Orano/URENCO expansion. The premium should be paid for the “narrow but real national-security position,” not for a “broad and exclusive monopoly.” That is the core of the report’s repeated point: the moat is narrow and real, not broad and exclusive.

  Jun 10, 2026
• QIf its core business is disrupted, does it have the DNA to reinvent itself? How does it handle mistakes and bad news?5/10

  A

  Conclusion: Centrus has a real track record of “disruption, bankruptcy, reinvention,” and this is its most underappreciated soft strength. But this reinvention came from policy tailwinds plus a correct technology bet, not founder-like endogenous regeneration DNA. The company’s current handling of “bad news” is more technical and reactive than proactive.

  Start with the “reinvention DNA.” It has a real and heavy record. Centrus’s predecessor, USEC, went through a textbook disruption and bankruptcy in 2014: ① the gaseous diffusion enrichment technology it operated was power-hungry and obsolete, fully displaced by centrifuges; ② the flagship “Megatons to Megawatts” program expired in 2013, removing cheap Russian feedstock; ③ its self-developed centrifuge project suffered a funding-chain break. Under this triple blow, USEC filed for Chapter 11 in 2014-03, reorganized the same year, and renamed itself Centrus. The stock once fell to about $1. It did not die. It moved the bet wholesale from “old diffusion technology” to “self-developed centrifuges + HALEU first mover,” and in 2023 became the carrier of the first “American-made” enrichment capability in 70 years. A company that can see its core business technologically obsoleted, go through bankruptcy, and climb back into the “national team” has proven an ability to reposition itself through a paradigm shift. That is a real, observable reinvention record, and it is more tested than the vast majority of pre-revenue peers (OKLO/SMR have never gone through an existential crisis).

  But be honest about the quality of this reinvention:

  • It looks more like “catching the right external policy cycle” than “endogenous antifragility.” The core drivers of this rebirth are the Russian uranium import ban, DOE’s multibillion-dollar rebuilding of domestic enrichment, and the AI power-demand narrative. These are external tailwinds Centrus does not control. If the policy direction reverses (funding fights, administrative changes, renewed Russian waivers), the same “reinvention” logic could be disproved in reverse. Its regeneration ability is highly dependent on a supportive policy environment, not self-contained.
  • It is not the kind of company where a founder controls the board and bets on a long-term vision. All directors + executives (14 people) together own only about 1%, while institutional ownership is about 71–74% (2025 DEF 14A). CEO Amir Vexler was parachuted in from Orano USA only in 2024. This means “reinvention” is more likely driven jointly by professional management + board + policy window, without an internal owner “willing to burn for ten years to win the bet.”

  Now look at “how it handles mistakes and bad news.” So far it looks technical and reactive, but disclosure is relatively candid. Centrus proactively disclosed many unfavorable facts in its 10-K: it acknowledged insufficient TENEX replacement sources, uncertainty over whether waivers can be obtained in time, the $900M task order still being “subject to negotiation,” no guarantee of funding, and disclosed earnings quality and dilution in a candid tone. This culture of “not hiding bad news” is a positive. But for truly disruptive bad news, such as the 2024-11 TENEX export license revocation that caused a one-day -10% stock drop and repeated SMR customer delays, its response has mostly been “acknowledge + wait for policy resolution,” rather than showing proactive countermeasures or strategic redirection.

  Practical judgment: Centrus’s reinvention DNA is real and has been tested by bankruptcy and survival. That is the hard base that distinguishes it from many “paper growth stocks.” But this reinvention is the product of “betting on the right external cycle,” depends on continued policy support, and lacks a founder-like endogenous regeneration engine. Its attitude toward bad news is candid (disclosure does not cover things up), but its handling is reactive (acknowledge risk, wait for policy and time). Give it credit for “not easily dying,” but do not mistake it for a company that can keep self-evolving without policy tailwinds.

  Jun 10, 2026
• QDoes management, especially the founder, have a long-term view and deep alignment with the company? Is it willing to sacrifice current profits for five to ten years out?4/10

  A

  Conclusion: This is Centrus’s weakest link under the Baillie framework. It is not founder-controlled, management’s economic alignment with the company is shallow (directors + executives together own only about 1%), and the CEO is a professional manager parachuted in only in 2024. But its actions in “sacrificing current profit for five to ten years out” are real; they are just driven more by the policy window than by an internal owner’s proactive long-term bet.

  Start with “economic alignment.” It is clearly weak. All directors + executives (14 people) together own only about 1% (about 169,096 shares, as of 2025-04), while institutional ownership is about 71–74% (2025 DEF 14A). There is no founder, no controlling shareholder, and no super-voting structure. This is a company that has gone through bankruptcy restructuring and is led by institutions and professional management. Compared with Baillie’s preferred growth-stock archetype of “founder heavily invested, interests deeply tied to the company,” Centrus sits almost on the opposite side: the decision-makers’ personal wealth is barely tied to the stock price, and there is no internal owner “staking his or her net worth on making a ten-year vision work.” This means long-term capital allocation is more vulnerable to short-term shareholder pressure, board cycles, and policy bargaining.

  Now look at “long-term vision and management quality.” The team is professional and relevant, but follows a professional-manager path. CEO Amir Vexler took office in 2024-01. He was previously CEO of Orano USA, making him a seasoned nuclear-fuel executive with highly relevant experience (even from the most direct competitor camp, giving him deep industry understanding). The chair is non-executive Mikel H. Williams. Management’s professionalism and industry understanding are not the issue. The issue is that this is professional governance under an employment relationship, not owner-operator mission drive.

  Finally, ask whether it is “willing to sacrifice current profit for five to ten years out.” In action, yes, and the evidence is hard:

  • Capex is stepping up by an order of magnitude, actively depressing current profit in exchange for future capacity. 2026 full-year capital deployment guidance is $350–500M, while FY2025 capex was only $19.7M. This is a major bet on Piketon commercial capacity that will only come online in 2029. Q1'26 net income fell -63% year over year to $10.0M, exactly the early pain of “spend first, returns later,” and the company is still pushing ahead despite knowing it will pressure near-term EPS.
  • It is willing to dilute shareholders to finance expansion. In FY2025, it raised net $523.7M through equity issuance and $782.4M through convertible debt, while share count has already risen +17% over the past year. Management chose to “dilute current shareholders and stockpile ammunition” to support long-term capacity, a classic “sacrifice today for tomorrow” stance.

  But the motivation needs to be labeled honestly: this “sacrifice today” is largely a move with the current, pushed along by the Russian ban + DOE funding window, rather than a management team making a contrarian all-in bet against market sentiment. Investing in expansion when policy is providing money and the industry is in favor is a much lower bar than “burning for ten years when nobody believes.” Its long-term investment is real, but closer to “adding chips at a good table” than to the Baillie ideal of “betting when the table is empty.”

  Practical judgment: Management is professional and is indeed suppressing current profit and accepting dilution for long-term capacity. That deserves recognition. But shallow alignment, no founder/controlling shareholder, a parachuted-in CEO, and long-term investment driven by the policy window rather than an endogenous mission make it clearly weak on Baillie’s “long-term vision + deep alignment” yardstick. For a “ten growth questions” stock, this is a structural shortcoming, not a minor blemish.

  Jun 10, 2026
• QIf it disappeared tomorrow, how much would customers miss it? Is its growth model sustainable and not dependent on harming society or regulators?5/10

  A

  Conclusion: On “indispensability,” if Centrus disappeared tomorrow, defense/national-security customers (NNSA) would miss it badly, and there would be almost no short-term substitute. Commercial nuclear customers would miss it only to a limited degree because peers such as URENCO USA and Orano can fill in. On “social and regulatory sustainability,” its growth direction is highly aligned with national strategy, energy security, and decarbonization. It is a rare stock whose growth is “encouraged” rather than “penalized” by regulators, and this dimension is a strength.

  Start with “indispensability.” It depends on customer type, and the conclusion is polarized:

  • Defense/national-security customers: highly indispensable. NNSA intends to procure certain enrichment activities from Centrus on a “single-source” basis because foreign-owned technologies (URENCO/Orano) are bound by “peaceful use” obligations and cannot be used for unobligated uranium material for defense purposes. In other words, in the defense subsegment, Centrus is almost the only compliant domestic U.S. option (FY2025 results release). If it disappeared, this demand would have no one to fill it in the short term. This is its hardest “miss factor.”
  • Commercial nuclear customers: missed, but replaceable. Centrus’s current commercial LEU mainly relies on “purchase and resale” (Russian TENEX, French Orano long-term contracts + inventory), essentially a trading/supplier business. Its current commercial self-produced enrichment capacity is effectively zero. For utility customers, peers such as URENCO USA (about 4.9 million SWU/year) and Orano can step in. Supply is tight today and replacement has cost and timing friction, but this is not “irreplaceable.”
  • Future HALEU customers: potentially highly indispensable, but the customers have not appeared yet. It is the only domestic HALEU producer that is operating and licensed by the NRC, theoretically a key supplier to advanced reactors such as TerraPower and X-energy. But these customers’ actual HALEU purchase volume today is roughly zero (SMRs are broadly delayed), so the “miss factor” is an option, not yet realized.

  Now look at “whether growth is sustainable and not dependent on harming society or regulators.” This is a strength for Centrus, and the direction is clean:

  • Its growth sits on a track actively encouraged by regulators. The U.S. government is using DOE $2.7B procurement + IRA funding to actively cultivate domestic enrichment, while the Russian uranium import ban clears the field for it. Its growth is part of the national energy-security strategy, not built on harming the public, evading regulation, or exploiting one side.
  • Social benefits are positive: nuclear energy is low-carbon baseload power, de-Russification improves national energy security, and domestic HALEU supports advanced reactors. These are socially welcomed directions. It does not have the internal contradiction where “the faster it grows, the more society is harmed” (unlike some businesses built on data abuse, environmental externalities, or regulatory arbitrage).
  • The offset to label: its “miss factor” is largely policy-granted rather than market-spontaneous. Once DOE’s multi-supplier policy lands (Orano/General Matter/URENCO expansion), its scarcity in the commercial market will be diluted. Nuclear nonproliferation, ITAR, and NRC licensing are both moats and a sign that its fate is highly tied to regulatory continuity. Administrative changes and funding fights are variables.

  Practical judgment: Centrus scores almost full marks on “social/regulatory sustainability.” It stands on the right side of national-strategy encouragement and regulatory escort, and its growth does not rely on harming anyone. On “indispensability,” it is polarized: defense customers cannot do without it (real moat), commercial customers can find substitutes (trader attributes), and HALEU customer indispensability is still an option. If it disappeared, the Pentagon would miss it most, not utilities. That confirms the “narrow but real moat” judgment: real, but narrow in the national-security subsegment.

  Jun 10, 2026
• QWhat are the unit economics of this business (gross margin, incremental returns)? Will they improve or deteriorate as scale grows? Where does the money it earns go?4/10

  A

  Conclusion: Centrus’s current unit economics are “trader-level mid-range gross margin + bottom-line profit flattered by non-operating items + cash flow being consumed by capex.” The LEU segment’s about 32% gross margin is acceptable, but earnings quality is weak (about 90% of net income comes from interest), incremental returns depend on the 2029 self-production ramp, and scale could theoretically improve them, but only after years of heavy reinvestment and dilution. The money it earns is basically all being poured into expansion.

  Start with gross margin and profit structure. The surface looks acceptable, but the base is thin:

  • LEU segment gross margin is about 32.2%, contributing almost all company gross profit (FY2025 10-K). But remember that the business today is mainly “purchase and resale”: buying from Russian TENEX and French Orano under long-term contracts, then selling to utilities. This is essentially a trading/supplier spread, not a self-produced cost advantage.
  • Technical Solutions segment (HALEU operations) gross margin fell from 19.1% the previous year to 5.9%, because it is priced on a “cost-plus-incentive-fee” basis, with thin fees and fluctuations by contract phase. It is a policy-incubation stage, not a cash cow.
  • Overall operating margin is only about 11.2% (FY2025), and TTM has fallen further to about 6.7%. The bottom-line net profit is heavily “watered”: of TTM net income of $60.6M, about 90% came from roughly $54M of interest/investment income generated by a $1.87 billion cash pile. Strip out investment income, and the core business has little left after interest and pensions. This is the easiest trap in judging unit economics: reported net income looks good, but core-business cash generation is actually weak.

  Now look at cash flow and incremental returns. The company is currently in a “net outflow + heavy reinvestment” phase:

  • Operating cash flow is far weaker than net income: FY2025 OCF was only $51M (net income $77.8M), and Q1'26 OCF turned negative at about -$35.1M (working-capital use such as inventory).
  • Where does the money it earns go? The answer is clear: all into expansion. FY2025 capex was $19.7M, and Q1'26 alone had already reached $23.2M. 2026 full-year capital deployment guidance is $350–500M: multibillion-dollar Piketon expansion + $560M+ Oak Ridge centrifuge manufacturing. The company pays no dividend and does no buybacks. All cash, including money raised through equity issuance and debt, is being invested in capacity that only comes online in 2029.

  Finally, ask whether unit economics improve or deteriorate with scale. Directionally they can improve, but only with conditions:

  • In theory, scale should improve unit economics: once it moves from “purchase and resale” to “self-produced SWU,” Centrus will no longer be constrained by the spread from Russian/French suppliers. The marginal cost structure of its own centrifuges should be better than the trading model. Enrichment is a high-fixed-cost, high-barrier industry, and incremental gross margins are usually high once utilization is full. This is the core of the bull case.
  • But before realization, it must first pass through a trough where “unit economics deteriorate”: before capacity ramps, massive capex will suppress free cash flow and ROIC. Add +17% share-count dilution over the past year, and incremental returns per share are a negative contribution in the short term. Domestic enrichment cost (around $1000/SWU·year capacity) also still carries a structural disadvantage versus the international market. Whether scale can deliver “cost down + utilization up” remains an unproven bet.

  Practical judgment: Centrus’s current unit economics have “trader characteristics”: mid-range gross margin, thin operating profit, interest-supported bottom line, and cash flow swallowed by capex. Its growth logic is a bet on a structural step-up in unit economics after 2029 self-produced capacity comes online. The direction makes sense, but it must first cross years of heavy reinvestment + dilution. Before giving it growth-stock credit for unit economics, we need to see self-produced gross profit truly scale, OCF stay positive, and ROIC emerge from the capex trough. Until then, this business is still some distance from a “larger scale, more profitable” flywheel, and every dollar earned is paying for 2029.

  Jun 10, 2026
• QWhat conditions must all hold for it to rise fivefold over ten years? Are those conditions realistic? What expectations are embedded in today’s stock price?3/10

  A

  Conclusion: For Centrus to rise fivefold over ten years (market cap from about $2.95B to about $15B), roughly 6–8 conditions must hold at the same time. Most of them are external variables it does not control (SMR deployment, SWU prices, continued DOE funding). This is not impossible, but it is a moderately optimistic blue-sky case, not the base case. Today’s stock price of about $149.66 (PE-TTM still about 57x, EV/EBITDA about 60x) already embeds considerable credit for “guidance delivery + HALEU expansion option.” The market is not treating it as cheap; it is pricing it as a “partly realized growth option.”

  Set today’s anchor first: the current stock price is about $149.66, with market cap about $2.95B (2026-06-09), already down about 68% from the 52-week high of $464.25. A fivefold rise over ten years means market cap must reach about $15B, or about 17.5% annualized. For a company whose revenue has been flat for nearly three years (about $450M) and whose core business relies on interest to support the bottom line, this requires a qualitative change in fundamentals.

  Conditions that must all hold for a ten-year fivefold outcome (with reality check):

  1. The HALEU/advanced-reactor market commercializes on schedule: TerraPower, X-energy, Oklo, and other SMR projects actually enter operation and buy HALEU in volume. Realism: low and worsening. TerraPower has already pushed Natrium to 2030/2031, and FOAK project slippage is normal. This is the largest single-point risk.
  2. Piketon commercial capacity starts in 2029 on schedule, without overruns, and ramps smoothly: multibillion-dollar capex, Fluor as EPC, long construction cycle. Realism: execution risk is very real, and nuclear-engineering overruns/delays are an industry chronic issue.
  3. SWU prices stay high or rise: spot SWU has already risen from about $56 to about $188/SWU, and it must remain firm at multi-year highs. Realism: medium. Prices are already high, further sharp upside is limited, and mean-reversion risk exists.
  4. DOE/NNSA funding and “single-source” procurement continue to materialize and expand: the $900M task order is still subject to negotiation and depends on federal budgets and policy continuity. Realism: medium, affected by administrative changes and budget fights.
  5. The “only” premium is not pierced by competition: but in the same round DOE has already backed Orano (a $5B/7.4M SWU plant) and General Matter, while URENCO is expanding by 50%. Realism: negative tilt, as the multi-supplier strategy is actively diluting exclusivity.
  6. Russian-feedstock backlash does not detonate: TENEX is currently the largest SWU supplier (through 2028), and embargo/waiver changes are a sword overhead. Realism: medium. Historically, one TENEX-related news item caused a one-day -10% move.
  7. Financing dilution does not run out of control: share count has already risen +17% over the past year, and a ten-year expansion period will require continued equity issuance/debt. Per-share value must still outrun dilution. Realism: medium-tight.

  Of these 7 items, 3–4 are external variables Centrus does not control, and they are not independent of one another (SMR delays simultaneously hurt capacity utilization and pricing). The joint probability of all holding is not high, so a ten-year fivefold outcome is a blue-sky case, not the base case.

  What expectations are embedded in today’s stock price? The current price implies about 57x PE-TTM and about 60x EV/EBITDA, while roughly 90% of that “E” is cash interest, not the core business. This means the market is already paying for “FY2026 guidance delivery + HALEU expansion option”, valuing it as a “partly realized growth option” rather than a “thin-profit trader.” The report’s three-scenario P/S framework shows the current price at about P/S 7x, in the middle of the “reasonable Base (6–8x, $138–184)” range. It is neither cheap enough to offer a margin of safety nor expensive enough to Avoid. In other words, today’s price already embeds a neutral-to-optimistic expectation that “the story works.” To earn fivefold returns, the full bull case must happen (P/S returns to 10–14x + revenue multiplies with capacity), not merely “no mistakes.”

  Practical judgment: A ten-year fivefold path exists, but it requires a long chain of external conditions to hold at the same time, while many face headwinds from delays or competitive dilution. Today’s price of about $149.66 leaves no margin of safety for that narrow path; it already gives the “growth option” substantial credit. This is the core arithmetic behind the report’s “Watch, ideal buy price ≤$120”: with catalysts pushed to 2029+ and high SMR execution risk, either fundamentals must be materially de-risked, or the price must fall another about 25% to provide an execution-risk cushion before odds turn favorable.

  Jun 10, 2026
• QWhy has the market not realized all this yet? Is it because the market does not understand, looks down on it, or cannot look far enough? What will become the “narrative inflection point”?3/10

  A

  Conclusion: The special thing about Centrus is that the market has not “failed to realize” the story. It has already realized it too much, then collectively retreated. The stock rose +264% in 2025 (intraday once +500%) and reached a $464 high, showing that the market had long understood the narrative of AI power demand → nuclear revival → domestic enrichment. The later roughly 68% drawdown to about $149.66 was not because the market “looked down on it,” but because investors understood that profit would be pressured first, capacity would not arrive until 2029, and most orders were contingent. If anything is not fully priced, it is “not looking far enough” and “huge disagreement”, not failure to understand.

  Break down “does not understand / looks down on it / cannot look far enough”:

  • It is not “does not understand.” About 16 analysts covering LEU still have a consensus “Buy,” with average price-target range around $222–279 (well above the current price), and the sell side understands this narrative clearly. The 2025 surge proves that retail and institutions both “got” the story. The opposite of not understanding is true: the market understood it so well that it once over-discounted it.
  • It is not “looks down on it.” Current valuation is about 57x PE-TTM, about 60x EV/EBITDA, and about 7x P/S. The market is giving it an option valuation, not the cheap valuation of a “thin-profit trader.” It has not been treated as a neglected orphan; it is priced as a “partly realized growth option.”
  • What is truly underpriced is “not looking far enough” and “pricing disagreement.” Catalysts are concentrated in 2029+, while the market’s attention cycle is short. Investors easily swing between the near-term pain of “Q1 profit -63%, OCF turning negative” and the long-dated “2029 capacity + HALEU option.” This difficulty of discounting long-term value into the present is the root of its violent valuation volatility (a 3.5x stock-price swing within 52 weeks while revenue was basically flat). More importantly, the disagreement at both ends is huge: sell-side average targets around $222–279 (seeing the expansion option), more bearish independent intrinsic-value models (after stripping out the cash pile), and short interest around 22–24% of float (highest in the group, versus peer average only about 8.6%). Bulls and bears assign drastically different prices to the same facts. That itself signals that “the story has not been fully digested,” not that “nobody discovered it.”

  What will become the narrative inflection point? The key is whether “contingent” can become “certain,” and whether “long-dated” can move closer:

  • Positive inflection points (fundamentals catch up with valuation): ① the $900M HALEU task order is formally signed + DOE funding lands (signature itself would be a major de-risking event); ② Piketon commercial-scale capacity construction milestones are met, firming up the 2029 timeline; ③ the first commercial (non-DOE) HALEU customer or new long-term contract appears, validating the shift from “contingent orders” to “hard orders” (about 77% of the current LEU backlog is contingent revenue); ④ national-security “single-source” procurement officially lands and is larger than expected. Any one of these could trigger a repricing round and could squeeze the 22–24% short interest.
  • Negative inflection points (valuation converges toward fundamentals): ① TENEX supply interruption/Russian-feedstock waiver changes; ② further delays or cancellations by SMR customers (see NuScale UAMPS and TerraPower); ③ new equity/debt financing announcements confirming dilution; ④ further sell-side target-price cuts (already happening: consensus has fallen from about $279 to about $269).

  Practical judgment: Centrus is not a “buried stock waiting to be discovered.” It is a stock that has been fully discovered, then collectively abandoned after the near-term pain became clearer, with severe bull-bear disagreement. The real information edge is not “whether one understands,” but “whether one is willing to discount 2029 long-dated value into today,” and that depends precisely on a series of de-risking events that have not yet happened. The narrative inflection points almost all sit on the line from “contingent orders → hard orders” and “long-dated capacity → milestone delivery.” Before those signals appear, the market will keep oscillating amid huge disagreement. That is the fundamental reason the report says “Watch, wait for signals,” not “chase in”: the market can already see the story; the de-risking that it needs to see has not happened yet.

  Jun 10, 2026